DOUGLAS EARL MARTIN (SVP, General Counsel) sold 3.9% of their position (22.90K shares) of ALLOGENE THERAPEUTICS, INC. on the open market
Open‑market sale worth $40.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/4/2026ACC: 0001362155-26-000002
Officer· SVP, General Counsel
Since Feb 2026
+668.65K
Net shares
Net buyer
$40.3K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
691.55K acquired · 22.90K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−22.90K
Price / share
$1.76
Trade value
$40.30K
% of position
3.9%
2/2/2026
587.85K→564.95K
Total
Net shares
−22.90K
Net value
-$40.30K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/2/2026 | S · Sale | −22.90K | $1.76 | $40.30K | 3.9% | 587.85K | 564.95K |
| Total | −22.90K | -$40.30K | ||||||
Derivative Transactions2
Stock Option (Right to buy)
Direct
Converts to
Common Stock
539.07K shares
Shares
+539.07K
Strike price
1.87
Held after
539.07K
Exercisable
—
2/2/2026
Restricted Stock Unit
Direct
Converts to
Common Stock
152.48K shares
Shares
+152.48K
Strike price
Held after
152.48K
Exercisable
—
2/2/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Direct | Common Stock539.07K shares | 2/2/2026 | A · Award | +539.07K | 1.87 | — | 539.07K |
| Restricted Stock Unit Direct | Common Stock152.48K shares | 2/2/2026 | A · Award | +152.48K | — | 152.48K |